Topics:

Tositumomab/Iodine-131 Tositumomab for Non-Hodgkin’s Lymphoma Patients Who Progressed After Treatment With Rituximab: Results of a Multicenter Phase II Study

Tositumomab/Iodine-131 Tositumomab for Non-Hodgkin’s Lymphoma Patients Who Progressed After Treatment With Rituximab: Results of a Multicenter Phase II Study

Tositumomab/iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy active in chemotherapy-relapsed or -refractory indolent (IN) or transformed indolent (TR) non-Hodgkin’s lymphoma. The current study was undertaken to assess overall response rate, duration of response, time to progression, and safety of tositumomab/iodine-131 tositumomab in patients previously treated with the chimeric anti-CD20 antibody rituximab (Rituxan).

Eligible patients had a confirmed diagnosis of IN, TR, or de novo follicular large cell (FLC) non-Hodgkin’s lymphoma and progressed after or failed to respond to rituximab. Thirty-eight patients were studied (Stanford [15], M. D. Anderson [13], U.S. Oncology [10]). Histologies included small lymphocytic (1), follicular small cleaved or mixed (25), FLC (3), and transformed (7).

Patient characteristics included a median age of 57 years, four prior chemotherapy regimens (68%), and marrow involvement (32%). Patients received a dosimetric dose (5 mCi iodine-131) and whole-body counts to calculate a therapeutic dose of 75 cGy (platelets > 150,000/µL) or 65 cGy (platelets 100,000 to 149,000/µL). All patients completed the therapeutic dose.

Toxicity was primarily hematologic and transient. Median absolute neutrophil count nadir was 1,200/µL and median platelet nadir was 90,000/µL. The median durations of grade IV neutropenia (6 patients) and thrombocytopenia (4 patients) were 9 and 29 days, respectively. No patients converted to human antimouse antibody-positivity after the therapeutic dose. Investigator-assessed confirmed responses to tositumomab/iodine-131 tositumomab (at least two assessments 4 weeks apart) by prior treatment with rituximab were as follows:

Median duration of response was 478 days. Median times to progression for responding and all patients were 566 and 182 days, respectively.

CONCLUSION: In conclusion, tositumomab/iodine-131 tositumomab is a safe and effective treatment strategy for patients who progress after or fail to respond to rituximab.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.